Skip to main content

MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma: 4 Medicare contractor policies compared

4 Local Coverage Determinations in the current Medicare Coverage Database export carry the title "MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma", between them covering 51 states and territories. The table below is the fastest way to see which version governs a given state and how far the versions have drifted.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Policies with this title
4
States covered
51
Versions with a coded article
0
Revision dates
2024-08-18 to 2026-05-28

Every version by contractor

Open a version for its full policy text, contracts, codes and related NCDs. Covered codes are the count of ICD-10-CM codes in the version's billing and coding article; a dash means the export attaches no coded article.

Local Coverage Determinations titled "MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma"
LCDContractorStatesRevisedCovered codesPolicy words
L39583Palmetto GBAAL GA NC SC TN VA WV2024-08-18—19
L39585CGS Administrators, LLCKY OH2026-05-28—19
L39589Noridian Healthcare Solutions, LLCAK AS AZ CA CNMI GU HI ID MT ND NV OR SD UT WA WY2026-01-22—19
L39614Wisconsin Physicians Service Insurance CorporationAK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY2026-05-28—19

Diagnosis lists compared

Fewer than two versions of "MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma" link a billing and coding article with a covered ICD-10-CM list in the current export, so there is no diagnosis-level comparison for this title; the policies differ in their text, effective dates and documentation requirements instead. The LCD coverage variation report compares every title where two or more contractors publish coded lists.

How to use the comparison

Start from the state where the service is furnished and open that contractor's version; its billing and coding article carries the diagnosis codes the claims system will test. For a group that bills in several jurisdictions, the version with the smallest covered list is the safe common denominator for pre-service review, and the version with the largest list shows what documentation can support an appeal elsewhere. The L39614 version is the one most searched for this title; the LCD lookup guide explains how jurisdictions are assigned, and the LCD hub lists every topic that more than one contractor has written.

For teams evaluating QuickIntell software

Where QuickIntell fits across jurisdictions

For teams working across MAC jurisdictions, evaluate how requirements, source policies and documentation review should be organized for each case. Confirm jurisdiction-specific scope and supported actions during a QuickAuth evaluation; compare claim and denial follow-up separately in QuickRCM.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

Why are there 4 LCDs called "MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma"?

Each Medicare Administrative Contractor writes its own Local Coverage Determination for its jurisdiction. 4 contractors publish a policy with this title covering 51 states; they often start from one contractor's text and then revise separately, so dates, criteria and diagnosis lists differ by jurisdiction.

Which "MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma" LCD applies to my claim?

The one written by the contractor that processes the claim: the A/B MAC for the state where the service is furnished, or the DME MAC region for equipment. The table lists each policy's states; open the policy for that jurisdiction and its billing and coding article.

How different are the diagnosis lists?

The current export attaches a coded billing article to at most one of these versions, so the comparison rests on the policy text and effective dates.

When were these policies last revised?

Revision effective dates run from 2024-08-18 to 2026-05-28. A claim is judged against the version in force on the date of service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

Policy metadata and code counts are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.